The rise and fall of Theranos, in one graphic
Theranos, the blood-testing startup with a $9 billion valuation, has had a turbulent year.
On Wednesday, the company announced major changes, including that its president and chief operating officer Sunny Balwani, who served as CEO and founder Elizabeth Holmes' second-in-command, is retiring.
Here's a review of the events that led up to this point over the last year.